微生物群
失调
医学
恶化
免疫学
肺
慢性阻塞性肺病
普雷沃菌属
厚壁菌
支气管扩张
囊性纤维化
梭杆菌门
阻塞性肺病
疾病
呼吸道疾病
呼吸道感染
铜绿假单胞菌
间质性肺病
免疫系统
呼吸系统
人体微生物群
流感嗜血杆菌
呼吸道
嗜血杆菌
肺功能
牙龈卟啉单胞菌
作者
Fares A. Qtaishat,Ahmad AlKayyat
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2025-09-27
卷期号:: PA4746-PA4746
标识
DOI:10.1183/13993003.congress-2025.pa4746
摘要
Background: Chronic respiratory diseases (CRD) significantly contribute to global morbidity and mortality. Disruptions in the lung microbiome are linked to disease progression, exacerbations, and impaired lung function. Hypothesis & Objectives: We hypothesize that CRD patients exhibit distinct microbial profiles. This review aims to explore microbial composition in CRD patients, assess shifts related to disease severity, and explore microbiota-immune interactions. Methods: A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane Library up to February 2025. Eligible studies examined lung microbiome characteristics in CRD patients and their associations with exacerbation rates, lung function decline, and inflammation. Two independent reviewers performed data extraction and quality assessment. Results: Twenty-nine studies were included. Most reported dysbiosis in CRD patients. In chronic obstructive pulmonary disease (COPD), Proteobacteria increased while Firmicutes declined. In asthma, Haemophilus was overrepresented, while Prevotella was depleted. Cystic fibrosis patients exhibited a reduced microbial diversity, often dominated by Pseudomonas aeruginosa and Staphylococcus aureus. Viral and fungal alterations were observed, which may influence immune responses. Lower alpha-diversity correlated with more frequent exacerbations and impaired lung function. Conclusions: Lung microbiome alterations, particularly diminished diversity and compositional changes, contribute to CRD progression. Microbial-immune interactions play a key role in disease severity. Standardized methodologies are needed to establish causality and explore microbiome-targeted therapies for CRD treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI